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Crystal structure of carboxypeptidase G2, a bacterial enzyme with
applications in cancer therapy
Siân Rowsell1†, Richard A Pauptit2, Alec D Tucker2‡, Roger G Melton3, 
David M Blow1 and Peter Brick1*
Background: Carboxypeptidase G enzymes hydrolyze the C-terminal glutamate
moiety from folic acid and its analogues, such as methotrexate. The enzyme
studied here, carboxypeptidase G2 (CPG2), is a dimeric zinc-dependent
exopeptidase produced by Pseudomonas sp. strain RS-16. CPG2 has
applications in cancer therapy: following its administration as an
immunoconjugate, in which CPG2 is linked to an antibody to a tumour-specific
antigen, it can enzymatically convert subsequently administered inactive
prodrugs to cytotoxic drugs selectively at the tumour site. CPG2 has no
significant amino acid sequence homology with proteins of known structure.
Hence, structure determination of CPG2 was undertaken to identify active-site
residues, which may in turn provide ideas for protein and/or substrate
modification with a view to improving its therapeutic usefulness.
Results: We have determined the crystal structure of CPG2 at 2.5 Å resolution
using multiple isomorphous replacement methods and non-crystallographic
symmetry averaging. Each subunit of the molecular dimer consists of a larger
catalytic domain containing two zinc ions at the active site, and a separate
smaller domain that forms the dimer interface. The two active sites in the dimer
are more than 60 Å apart and are presumed to be independent; each contains a
symmetric distribution of carboxylate and histidine ligands around two zinc ions
which are 3.3 Å apart. This distance is bridged by two shared zinc ligands, an
aspartic acid residue and a hydroxyl ion.
Conclusions: We find that the CPG2 catalytic domain has structural homology
with other zinc-dependent exopeptidases, both those with a single zinc ion and
those with a pair of zinc ions in the active site. The closest structural homology is
with the aminopeptidase from Aeromonas proteolytica, where the similarity
includes superposable zinc ligands but does not extend to the rest of the active-
site residues, consistent with the different substrate specificities. The mechanism
of peptide cleavage is likely to be very similar in these two enzymes and may
involve the bridging hydroxyl ion ligand acting as a primary nucleophile. 
Introduction
Enzymes of the carboxypeptidase G class cleave the C-ter-
minal glutamate moiety from folic acid (Fig. 1) and its 
analogues, such as methotrexate. The key role of reduced
folates as coenzymes in many biochemical pathways,
including those leading to DNA synthesis via the pyrim-
idines and purines, has made folic acid a target molecule
for chemotherapy. Tumour cells grow rapidly and have a
high rate of nucleic acid synthesis. Depletion of folic acid
has cytotoxic effects primarily in replicating tissue, and can
inhibit the growth of tumours with high folic acid require-
ments [1]. Carboxypeptidase G enzymes directly deplete
folate by hydrolytic removal of its glutamate moiety [2].
In cancer therapy, methotrexate (4-amino-N10-methyl-
pteroyl-glutamate) is commonly used to deplete the pool of
reduced folate. It inhibits dihydrofolate reductase (DHFR)
[3], which catalyses the reduction of folates into the biologi-
cally active tetrahydrofolate form, essential in the biosyn-
thesis of all folate coenzymes. The carboxypeptidase G
enzymes can be used in rescue therapy following toxic
high-dose methotrexate regimes [4–7], because hydrolysis
of methotrexate produces 4-amino-N10-methylpteroate that
is about 100-fold less active as an inhibitor of DHFR [8].
The carboxypeptidase G enzymes also hydrolyse subfrag-
ments of folic acid and, in particular, glutamated benzoyl
nitrogen mustards (see below). 
Carboxypeptidase G enzymes have been isolated from a
number of pseudomonads [9–12] and a Flavobacterium sp.
[13], and all of them have very similar substrate speci-
ficities. The enzyme studied here, carboxypeptidase G2
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(CPG2), is a zinc-dependent metalloenzyme produced by
Pseudomonas sp. strain RS-16 as a homodimer of molecular
weight 2×41800Da [11,14]. Atomic absorption analysis
indicates binding of four zinc ions per dimeric molecule
[11]. The N-terminal amino acid of CPG2 is designated 23
because a 22 amino acid N-terminal signal peptide is
cleaved upon the enzyme’s localization to the periplasm
[14,15]. CPG2 has a high affinity for both 5-methyl-tetrahy-
drofolate, the predominant circulatory form of folate in
mammals, and methotrexate [15].
The inadequate selectivity between tumour and normal
cells of most anticancer drugs is well known and their toxi-
city to normal tissues is dose-limiting [16]. Recently, pro-
drugs have been developed that are designed to be
converted to the active drug only at the tumour site. A
conjugate of an enzyme and an antibody to a tumour-spe-
cific antigen is administered first. After a delay to allow
residual enzyme conjugate to be cleared from the blood, 
a relatively non-toxic prodrug is administered, which is
activated by the tumour-located enzyme. This two-phase
approach has been termed antibody-directed enzyme-
prodrug therapy (ADEPT; reviewed in [17]). Another
advantage of this procedure is that a single enzyme mol-
ecule is capable of activating many prodrug molecules.
Furthermore, the drug released is small and diffuses easily
through poorly vascularized tumours, thereby reaching
cells in tumour masses that are inaccessible to antibodies
[16,18]. 
CPG2 may be used in ADEPT to cleave glutamate from
glutamated benzoyl nitrogen mustards, producing nitro-
gen mustards with effective cytotoxicity against tumour
cells [19,20]. The advantage of using a non-mammalian
enzyme such as CPG2, which has no human analogue, is
that the prodrug is not activated by host enzymes at non-
tumour sites. Several enzyme–prodrug systems are being
evaluated, but only the carboxypeptidase G2 system has
thus far entered clinical trials [17].
The three-dimensional structure determination of CPG2
was undertaken to identify the active site of the enzyme
and to allow modification of the protein and/or substrate
with a view to improving the therapeutic properties of the
system [21]. We present the three-dimensional crystal
structure of CPG2 from Pseudomonas sp. strain RS-16 that
has been determined at 2.5 Å resolution. In addition, we
compare this three-dimensional structure with other zinc-
dependent exopeptidases.
Results and discussion
CPG2 crystallizes in space group P21, with two dimeric
molecules in the crystallographic asymmetric unit. The
three-dimensional crystal structure was determined by 
the multiple isomorphous replacement (MIR) methods
(Table 1), together with real-space non-crystallographic
symmetry averaging. The structure was refined against
2.5Å resolution data to a crystallographic R factor of 19.6%
and a free R factor of 22.4%. The molecular model for
each of the four monomers has good stereochemistry and
includes 389 out of 393 residues and two zinc ions in the
active site. Three N-terminal residues (23–25) and the
C-terminal residue (415) can not be recognized in the
electron density. 
Overall structure
The structure of the CPG2 subunit consists of two
domains (Fig. 2) — a catalytic domain, which supplies the
ligands for the two zinc ions in the active site, and a
second domain. The latter domain forms the dimer inter-
face through hydrophobic interactions between helices, as
well as through hydrogen bonding between two b strands,
one from each monomer, forming a continuous b sheet
across the dimer (Fig. 3). The subunit topology is illus-
trated in Figure 4. The two active sites in the dimer are
62Å apart, and we assume that they act independently. 
The catalytic domain
The catalytic domain comprises residues 23–213 and 326–
415. Both the N and C termini of the polypeptide chain
are in this domain. The hydrophobic core of the catalytic
domain consists of an eight-stranded b sheet sandwiched
between a helices. The b sheet contains two antiparallel
(1 and 2) and four parallel strands (4, 3, 5 and 8), and then
two additional parallel strands (6 and 7) that are strongly
rotated with respect to the main sheet. The zinc ions are
located at the C-terminal end of the four central parallel
b strands. In addition, there is a second b sheet containing
four shorter antiparallel b strands located on the surface 
of the molecule (Fig. 4).
The dimerization domain
The dimerization domain of CPG2 consists of a single, 110-
residue insertion between strands 6 and 7 of the b sheet 
in the large domain (Fig. 4), comprising residues 214–
325. The insertion folds into a four-stranded antiparallel
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Figure 1
Enzymatic hydrolysis of folate (R1 = OH, R2 = H) or methotrexate
(R1 = NH2, R2 = CH3) by CPG2.
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N
N
N
N
R1
H2N
CH2
N
R2
C
O
N
H
C
COO-
H
CH2CH2COO
-
b sheet, flanked on one side by two a helices (Fig. 2). This
domain is topologically similar to the RNA-binding domains
of phenylalanyl-tRNA synthetase [22], human hnRNP C
proteins [23] and U1 small nuclear ribonucleoprotein A 
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Table 1
Data collection and phasing statistics.
Native Derivatives
nat1 nat2 K2Pt(NO2)4 K2PtCl4 K2Pt(NO2)4/
K2(OsCl6)
Source CuKa Daresbury CuKa CuKa CuKa
station 9.6
Wavelength (Å) 1.54 0.92 1.54 1.54 1.54
Maximum resolution (Å) 3.0 2.5 3.0 3.5 4.0
No. of measurements 46 018 224 872 56 064 82 823 24 338
Independent reflections 34 205 62 936 34 709 23 779 13 767
Completeness (%)* 88.5 93.9 89.4 96.3 82.5
(71.3) (90.4) (47.9) (97.0) (77.4)
Rmerge (%)*† 4.7 6.9 5.1 5.7 13.9
(14.5) (16.8) (12.1) (9.5) (23.1)
Concentration of
heavy-atom salt (mM) 5.0 5.0 5.0/5.0
Soak time (days) 2 1 4
Number of sites 8 8 12
Riso (%)‡ 14.2 17.0 24.7
Phasing power§ 1.21 1.18 1.24
Rcullis# 0.72 0.74 0.74
*Values for the outermost resolution shell are given in parentheses. †Rmerge = Σh Σi | Ih,i –
_
Ih | / Σh Σi Ih,i (×100%), where Ih,i is the intensity of a
measured reflection i and 
_
Ih is the average intensity for this reflection. ‡Riso = Σh | Fderh – Fnat1h | / Σh Fnat1h (×100%). §Phasing power = <heavy
atom structure factor> / <lack-of-closure>. #Rcullis = <lack-of-closure> / <isomorphous difference> for centric reflections only.
Figure 2
Stereo view of the CPG2 subunit a carbon
backbone, with some sequence numbering.
The catalytic domain is at the top of the figure,
with the dimerization domain below. The
active-site zinc ions are represented by small
circles. (Figure generated using the program
MOLSCRIPT [58].)
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[24], as well as to acylphosphatase [25]. Interestingly, 
the propeptides of carboxypeptidases A and B include 
a 70 amino acid segment that has the same fold 
[26,27] as that of the dimerization domain of CPG2.
However, these N-terminal propeptide segments have
no sequence homology with CPG2 and are in a different
position relative to the catalytic domain in the overall
structure.
Two zinc ions at the active site
In the active site of CPG2, sidechain ligands are sym-
metrically disposed about two zinc ions (zinc 1 and 
zinc 2), which are separated by a distance of 3.3 Å (Fig. 5;
Table 2). Zinc 1 is coordinated by carboxylate oxygens 
of Asp141 and Glu176 and by His385. Zinc 2 is coordi-
nated by the other carboxylate oxygen of Asp141, by a
carboxylate oxygen of Glu200 and by His112. Thus, each
zinc ion has one histidine, one glutamate and one aspar-
tate ligand, where Asp141 is in fact a bridging ligand
between the two zinc ions. There is also a bridging water
molecule (Fig. 5).
The coordination of both zinc ions is approximately tetra-
hedral. Glu200 and Glu176 may coordinate the zinc ion
with both carboxylate oxygens in a bidentate manner. The
coordination of each zinc ion has the same chirality, and
the zinc ligands are related by approximate twofold sym-
metry about an axis joining Cb of Asp141 and the water
molecule.
Structural homology within the exopeptidase family
The structure of the catalytic domain of CPG2 shows a
striking similarity to those of both the Aeromonas proteolyt-
ica and bovine lens leucine aminopeptidases (AMP and
LAP), each of which have dinuclear zinc sites [28,29], and
the carboxypeptidases A, B and T (CPA, CPB and CPT)
with mononuclear zinc sites [30–32]. These enzymes all
contain the eight-stranded b sheet and six (CPA, CPB
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Figure 3
Ribbon diagram of the CPG2 dimer. One
subunit is coloured blue and the other is
coloured yellow. The magenta spheres
represent the active-site zinc ions. (a) Viewed
in the same orientation as Figure 2.
(b) Orthogonal view of the CPG2 dimer
showing the continuous b sheet across the
two subunits forming the dimer interface.
(Figure generated using the program
MOLSCRIPT [58].)
and CPT) or seven (CPG2, AMP and LAP) structurally
equivalent helices (Fig. 4). In all these enzymes, the zinc
ions are located at the C-terminal end of the four central
parallel b strands. Structural similarity between CPA and
LAP was reported by Artymiuk et al. [33], and that
between CPA and AMP by Chevrier et al. [28]. 
The structure of the catalytic domain of CPG2 was com-
pared with that of AMP, CPA and LAP. The CPG2 cat-
alytic domain shares more extensive structural homology
with AMP than with the other enzymes. The CPG2 cat-
alytic domain is mostly made up of the structural motif
that is conserved in these four enzymes (Fig. 6). More
than half (56%) of the AMP a carbon atoms superpose on
those of the catalytic domain of CPG2 with a separation of
less than 2.5Å (root mean squares [rms] separation is
1.44Å). The zinc ligands are conserved in CPG2 and AMP,
except that the homologue of Glu200 in CPG2 is aspartate
(Asp179) in AMP. In addition to the insertion of the
dimerization domain, there are several other insertions
and deletions in loops of CPG2 that are absent in AMP.
There is 30% amino acid sequence identity between 
the bacterial carboxypeptidase T and the mammalian 
pancreatic carboxypeptidases A and B, that share a 48%
sequence identity [32]. However, despite being struc-
turally homologous, the four representative sequences
(CPG2, CPA, LAP and AMP) show no detectable amino
acid sequence homology. When amino acid sequences are
aligned according to structural similarity (data not shown),
only one amino acid, Gly145, is conserved among the 
four sequences. The greatest sequence similarity occurs
between CPG2 and AMP where 42 residues (out of 291
AMP residues, corresponding to 14%) are identical. These
identical residues include four of the five zinc ligands, but
the homology does not extend to the rest of the active-site
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Figure 4
Overall topology of the carboxypeptidase G2
enzyme. (a) Topological diagram illustrating
the secondary structural elements coloured by
subdomain. The arrows represent b strands,
and the circles represent helices. The
secondary structure was assigned on the
basis of mainchain hydrogen bonding using
the algorithm of Kabsch & Sander [59]. The
secondary structural elements belonging to
the catalytic domain are coloured pink or grey
and those of the dimerization domain are
coloured green. The secondary structural
elements conserved in LAP, AMP, CPA, CPB
and CPT are coloured pink and are numbered.
The first helix (helix A) is missing in
carboxypeptidases A, B and T. (b) Schematic
drawing showing the location of the
subdomains in the amino acid sequence,
using the same colouring scheme.
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residues, consistent with the different substrate specifici-
ties of the two enzymes. The remaining identical residues
occur in regions where they are required to maintain the
structural integrity of the fold. Therefore, in terms of
sequence, structure and the details of the active site, the
catalytic domain of the bacterial CPG2 is more similar to
the bacterial dinuclear zinc-containing AMP from A. prote-
olytica than to the mammalian enzymes. 
The zinc-dependent exopeptidases discussed here are
monomers, except for CPG2, which is a dimer, and LAP,
which is a hexamer. Like the CPG2 monomer, a subunit of
LAP consists of a catalytic domain (homologous to the cat-
alytic domain of CPG2) and an oligomerization domain.
The N-terminal oligomerization domain of LAP mediates
trimer–trimer interactions and does not appear to par-
ticipate directly in catalysis [29]. This domain is not 
structurally similar to the dimerization domain of CPG2;
instead it consists of a five-stranded b sheet, containing
four parallel strands and one antiparallel strand, sand-
wiched between four a helices.
Non-proline cis-peptide bond
In CPG2 there is a cis-peptide bond between the active-
site residues Asp141 (the zinc-bridging aspartic acid) and
Asp142. This conformation is stabilized by a network of
hydrogen bonds. This cis-peptide superposes on the cis-
peptide linking Asp117 (the zinc-bridging aspartic acid)
and Asp118 in AMP. 
Cis-peptide bonds in proteins are most commonly found
between a proline and the preceding residue. In the X-ray
crystal structures analysed by Stewart et al. [34], 6.5% of
the sequence X–Pro, where X may be any residue, were
found to be in the cis conformation; for non-proline
residues, the corresponding figure was only 0.05%. In
spite of the low occurrence, other zinc-containing car-
boxypeptidases also contain non-proline cis peptides at the
active site, although they are not topologically equivalent
to the CPG2 and AMP cis peptides. In carboxypeptidases
A and B, one zinc ligand (His196) is adjacent to a cis-
peptide bond formed between Ser197 and Tyr198, which
is involved in catalysis; there is a corresponding cis peptide
(Thr205–Tyr206) in carboxypeptidase T. The observation
that non-proline cis-peptide bonds generally occur in those
regions of a structure intimately associated with catalysis
indicates a functional role for these cis-peptide bonds [34]. 
Catalytic mechanism
The carboxypeptidases CPA, CPB and CPT employ two
histidines and one glutamate to coordinate a single zinc ion
[30–32]. There is another glutamate nearby (Glu270, CPA)
which can hydrogen bond to the metal-bound water mol-
ecule, activating it by polarization in a manner analogous
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Figure 5
Stereo view of the active site of CPG2, viewed
in a similar orientation to Figure 2, showing
the two zinc ions and their ligands in ball-and-
stick representation with atoms in standard
colours. The bridging active-site water
molecule is indicated as a light blue sphere.
Also shown is Glu175, which is likely to
promote the attack of the water molecule on
the substrate (see text). (Figure generated
using the program MOLSCRIPT [58].)
Table 2
Zinc–ligand distances.*
Ligand Ligand–Zinc 1 (Å) Ligand–Zinc 2 (Å)
Glu176 Oε1 2.5
Glu176 Oε2 2.1
His385 Nε2 2.0
Asp141 Od1 2.1
Asp141 Od2 2.0
Glu200 Oε1 2.0
Glu200 Oε2 2.5
His112 Nε2 2.0
*Average for all four subunits in the asymmetric unit. During refinement
the zinc–ligand distances were restrained to be greater than 1.92 Å.
The average zinc–zinc distance is 3.3 Å.
to the proposed mechanism of peptide cleavage for ther-
molysin [35]. 
The active sites of CPG2, AMP and LAP contain two zinc
ions. In CPG2, the zinc ions are bridged by a water mol-
ecule and Asp141; in AMP, the bridging acid group is the
homologous Asp117 [28]. In LAP, as well as a bridging
water molecule, there are two bridging acid groups that
are located in different parts of the structure [36]. The
active sites of CPG2 and AMP are extremely similar and
superpose surprisingly well (Fig. 7). The zinc ligands are
supplied by the same secondary structural elements and
have similar coordination spheres. 
The crystal structure of AMP complexed with a hydroxam-
ate inhibitor has recently been determined [37]. Hydrox-
amic acids are metal chelators, which form bidentate
complexes with transition metal ions. The structure of the
complex indicates that no major conformational changes in
the protein occur on inhibitor binding; the same is true for
LAP [36] and may be expected for CPG2. The hydroxam-
ate molecule is positioned in the AMP active-site pocket
so that the hydroxyl group bridges the two zinc ions,
replacing the water present in the unliganded structure.
The sidechain carboxylate oxygens of Glu151 in AMP
form the key interaction with the hydroxamate group of
the inhibitor [37]. Glu175 of CPG2 superposes on Glu151
of AMP, suggesting it has an analogous role in catalysis.
The conservation of this glutamate and a bridging water
molecule suggests that the hydrolytic mechanism of AMP
and CPG2 may be closely related to those of mono-zinc-
containing peptidases; hence, we propose that Glu175 (in
analogy to Glu151 in AMP) plays the role of a general base
in hydrolytic catalysis in CPG2 and the bridging water
ligand acts as the attacking hydroxyl ion nucleophile.
In the complex between AMP and a hydroxamate inhibitor,
the N-terminal phenylalanine residue of the inhibitor lies
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Figure 6
The conserved structural motif in the
exopeptidase family. Ribbon diagrams of
(a) the catalytic domain of CPG2, (b) AMP,
(c) the catalytic domain of LAP and (d) CPA.
The secondary structural elements conserved
in CPG2, LAP and AMP are coloured purple,
non-conserved regions are shown in grey. All
except the first helix (helix A) are also
conserved in CPA, CPB and CPT. In AMP,
this first helix is split into two consecutive
helices at the point where the CPG2 helix has
a kink caused by a proline (Pro41). (Figure
generated using the program MOLSCRIPT
[58].)
in a hydrophobic pocket formed by the aromatic sidechains
Tyr225, Phe244, Phe248 and Tyr251 [37]. In contrast, the
equivalent region of the active site in CPG2 leaves space to
accommodate the large pteroate moiety of folic acid.
Speculative proposals can be made as to which residues
may be involved in substrate binding in CPG2. The
charged residues Arg324 (from the dimerization domain)
and Lys177 are both located near the active site. Arg324
appears too far away from the active-site zinc ions (approx-
imately 8Å) to take a catalytic role, but it is probably
involved in binding to the glutamate sidechain of the 
substrate. Site-directed mutagenesis studies in which
Arg324 was replaced by an alanine residue resulted in a
mutant with very low activity against methotrexate (RGM,
unpublished results). Lys177 may also interact with the
glutamate moiety of the substrate; this would require
slight rearrangement of the mainchain, which is conceiv-
able as Lys177 is located in a loop region of the structure.
Further insights into the enzymatic mechanism of CPG2
await the structure determination of suitable enzyme–
ligand complexes.
Evolutionary relationships
Although the enzymes discussed here have equivalent
topologies, their active sites are different. They carry out
the same type of reaction but on different substrates. Is this
group of enzymes related by divergent evolution from 
a common ancestor, by convergent evolution towards a
simple common stable fold, or by convergent evolution
towards a structural arrangement dictated by a particular
functional requirement? In the case of the exopeptidases,
convergent evolution towards a simple common fold seems
improbable because the common folding motif is a complex
structure, further complicated by the inclusion of zinc ions
and cis peptides. Convergent evolution to a similar active
site dictated by function, as is exemplified by chymotrypsin
and subtilisin [38], does not seem relevant to the similarity
of gross tertiary structure seen here. The striking structural
similarity in the exopeptidase family strongly suggests that
they have originated from an ancestral peptide cutter and
have evolved to have different peptidase specificities. This
is in agreement with the conclusions made by Artymiuk et
al. [33], who proposed a divergent evolutionary relationship
between LAP and CPA. 
Biological implications
Carboxypeptidase G2 (CPG2) catalyses hydrolytic cleav-
age of the C-terminal glutamate moiety from folic acid
and its analogues. Folates are essential coenzymes in
many biochemical pathways, including synthesis of DNA
via the pyrimidines and purines. Folate analogues, such
as methotrexate that inhibits dihydrofolate reductase, can
be used to treat tumour cells with a high requirement 
for folic acid. CPG2 can be used in cancer therapy in two
ways. Firstly, as rescue therapy to remove toxic levels 
of methotrexate, by enzymic hydrolysis to a less toxic
product. Secondly, CPG2, coupled to antibodies specific
for tumour cells, can activate prodrugs, such as gluta-
mated nitrogen mustards, specifically at the tumour site.
Both these therapies utilize the ability of CPG2 to cleave
C-terminal glutamate moieties.
The structure of CPG2 reveals it to be a dimer with two
domains in each subunit. One domain, which consists
predominantly of a b sheet, forms the interactions at 
the dimer interface, while the second is the catalytic
domain. The catalytic domain of CPG2 contains two
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Figure 7
Stereo view of the active sites of CPG2 (cyan)
and AMP (green) when the conserved
secondary structural elements are superposed,
viewed as in Figure 5. Atoms are shown in
standard colours. (Figure generated using the
program MOLSCRIPT [58].)
zinc ions bound to active-site ligands, and it shows 
striking structural similarity to two other proteolytic
enzymes with dinuclear zinc catalytic sites. Hexameric
leucine aminopeptidase (LAP) also has two domains in
each subunit, one consisting predominantly of b struc-
ture mediates trimer–trimer interactions of the other
subunits, but is quite unlike the dimerization domain 
of CPG2. The catalytic domain of LAP is homologous 
to that of CPG2. Aeromonas proteolytica aminopeptidase
(AMP) is monomeric and has only one domain.
Despite the lack of detectable sequence homology, the
catalytic domain of CPG2 has clear structural homology
to the other di-zinc peptidases. It is particularly alike in
structure to AMP, whose zinc ligands are almost identi-
cal, and whose active sites superpose accurately. There
is a more remote, but clearly detectable structural simi-
larity with the mono-zinc carboxypeptidases (CPA,
CPB and CPT). The conserved features within this
group of enzymes indicate the requirements of the cat-
alytic site. The strong structural similarity of the cat-
alytic domain of the carboxypeptidase CPG2 and the
aminopeptidase AMP, and their weaker similarities with
the other zinc-dependent peptidases, suggests that they
all diverged from an ancestral peptide cutter.
The two zinc ions in CPG2 and in AMP are each tetrahe-
drally coordinated to two carboxylate moieties, a histidine
and a water molecule (more probably a hydroxyl ion).
The same residue (Asp141, CPG2) coordinates both zinc
ions, which are also bridged by the hydroxyl ion. This ion
is believed to act as the primary nucleophile of the active
site, and may be displaced by the hydroxide group of a
hydroxamate inhibitor; this would explain the mecha-
nism of inhibition. In CPG2, the Asp141–Asp142 peptide
bond is in the cis conformation, as is the corresponding
Asp–Asp bond in AMP, and cis peptides also exist close
to the active site in CPA, CPB and CPT. The functional
role of the cis conformation appears related to the precise
geometrical arrangement required for catalysis.
The dimerization domain of CPG2 is a single peptide
chain with topological similarities to several RNA-
binding domains and the propeptides of carboxypepti-
dases A and B. It is likely to fold independently. It
contains Arg324, which may be a key residue involved
in substrate recognition. 
The structure has important implications for the design 
of targeted tumour peptidases and prodrugs. Most anti-
cancer drugs have inadequate selectivity between normal
and tumour cells. Therefore, design of tumour-targeted
drugs based on the structure of CPG2 could have far
reaching consequences for cancer therapy. The struc-
tural data on CPG2 reported here may allow the design of
methotrexate-degrading enzymes with altered specificity.
Materials and methods
Crystal data
Lloyd et al. [39] reported the crystallization of CPG2 in space group
C2. These crystals were found to have variable cell parameters and
were not suitable for structural studies using the isomorphous replace-
ment method. A modification of the crystallization protocol [40] yielded
crystals that were more amenable to structural analysis and can be
summarized as follows. Purified recombinant CPG2 was produced as
previously described [11,15]. Hanging drops [41] were formed by
mixing 4 ml of 16–20 mg ml–1 enzyme solution with 4 ml of a reservoir
solution, containing 10–12% PEG 4000 (w/v), 200 mM zinc acetate,
200 mM Tris (pH 7.2) and 10% glycerol (v/v). Equilibration of the drops
at 18°C or 20°C with the reservoir solution yielded crystals with typical
dimensions 400 ×400 ×400 mm within a few days. The crystals are of
space group P21 with unit cell parameters a = 81.26 Å, b = 105.28 Å,
c = 122.19 Å and b = 109.54°. The crystallographic asymmetric unit
contains four protein subunits, corresponding to a solvent content of
58% [42].
The crystals diffract to at least 1.9 Å resolution when using a synchro-
tron source, but the quality of the high-resolution data degrades rapidly
as the crystals are very sensitive to radiation damage. Room tempera-
ture rotating anode X-ray data to 3.0 Å from the native (nat1; Table 1)
and derivative crystals used for phasing were collected either on a FAST
television area detector equipped with a CAD4 Enraf-Nonius goniostat,
or on a 30 cm diameter MarResearch image plate, using graphite-mono-
chromatized CuKa X-radiation. The program MADNES [43] was used to
process the data collected on the FAST, and the data collected on the
MarResearch image plate were processed with a version of XDS [44]
adapted for use with image plates. Twelve crystals were used to collect
a native data set to 2.5 Å at the Synchrotron Radiation Source at Dares-
bury, UK (nat2; Table 1). These images were evaluated using a modified
version of MOSFLM (A Leslie, personal communication) for processing
image plate data. The CCP4 suite of programs [45] was used for the
data reduction and subsequent data handling. A summary of the data
collection and processing is given in Table 1.
Structure determination
The gel filtration and denaturing-gel electrophoresis studies of Sher-
wood et al. [11] indicated that CPG2 is a dimer of identical subunits.
Self-rotation function calculations indicated that the four subunits in the
asymmetric unit are related by three mutually perpendicular local
twofold axes. 
Initial phases were determined by MIR using two platinum derivatives
and a platinum/osmium double derivative (Table 1). Initial SIR phases
were calculated from the refined positions of two platinum sites per
asymmetric unit from the K2Pt(NO2)4 data. Additional heavy-atom sites
were located using difference Fourier maps. The positions and occu-
pancies of the heavy-atom sites were refined with the Patterson-space
refinement program VECREF [45,46]. Phases were calculated using
the program MLPHARE [45,47]. 
Final MIR phases were calculated using a set of eight common platinum
sites (although different occupancies were observed) for K2Pt(NO2)4,
K2PtCl4 and the double derivative, together with four osmium sites in
the double derivative. No anomalous data were included in the heavy-
atom refinement and phasing. The calculated phases have an overall
figure of merit of 0.44 for data between 20 and 3.0Å resolution.
The 3.2 Å MIR phases were improved by automated solvent flattening
and solvent ‘flipping’, a density modification technique in which the fea-
tures of the solvent are inverted rather than flattened [48,49]. The elec-
tron-density map calculated using the combined phases showed a
substantial improvement over the original MIR map. Small regions of
secondary structure could be identified, but the connectivity of most of
the map was poor, making chain tracing ambiguous. From the skele-
tonized representation [50] of the solvent-flattened map, it was possi-
ble to locate the molecules within the asymmetric unit of the crystal. 
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The asymmetric unit could be seen to contain two dimers packed
together in such a way as to give rise to 222 non-crystallographic sym-
metry (ncs). The position at which the 222 ncs axes intersect is in a
large region of solvent. It was not possible at this point, from the skele-
tonized electron density [50], to define the boundary between the sub-
units, between one dimerization domain and its ncs mate. A protein
envelope was therefore created from the skeletonized density of one
catalytic domain and two dimerization domains. The non-crystallographic
operators obtained from the self-rotation function and the position of the
centre of the 222 non-crystallographic symmetry, were refined by real-
space density correlation using a program from the RAVE package [51].
Iterative real-space averaging dramatically improved the quality of the
electron-density map. The envelope manipulation and averaging proto-
cols were performed using RAVE.
Model building and crystallographic refinement
The resultant 3.2 Å averaged electron-density map clearly showed the
topology of the protein. The map was of sufficient quality that it was
possible to build a polyalanine model for most of one monomer by
fitting fragments from a database of highly refined structures [52]. The
positions of the two zinc ions per monomer were identified by contour-
ing the map at 6s. Starting with the zinc ligands, the amino acid
sequence could be fitted unambiguously along the chain tracing to give
an initial model that included 379 residues out of a total of 393.
The model was then refined using the program X-PLOR [53], restrain-
ing the model with the Engh and Huber stereochemical parameters
[54], against a 2.5 Å native data set that had not been used for MIR
phasing (nat2; Table 1). A random sample containing 4% of the total
data (2536 out of 62936 unique reflections) was excluded from the
refinement, and the agreement between calculated and observed
structure factors for these reflections (Rfree) was used to provide an
unbiased indicator of the accuracy of the model and to monitor the
course of the refinement procedure [55].
An initial round of rigid-body refinement was carried out to 3.0 Å resolu-
tion, with each monomer treated as a separate rigid body, followed by
positional refinement in which the four subunits in the asymmetric unit
were constrained to be identical. Examination of an averaged electron-
density map calculated with coefficients (3Fobs–2Fcalc) and model
phases allowed the gaps in the polypeptide chain to be closed. The
refinement of the atomic positions was alternated with the refinement
of the atomic temperature factors, enforcing strict ncs and applying a
bulk solvent correction. When the R factor had dropped below 26%
(Rfree = 26.9%), water molecules were added at geometrically reason-
able positions at which the electron density was greater than 3s in the
averaged (Fobs–Fcalc) map.
When the R factor had dropped below 23% (Rfree = 23.9%), maps with
coefficients (3Fobs–2Fcalc) and (Fobs–Fcalc) were calculated but not
averaged, and the crystallographically independent monomers exam-
ined separately. Several more rounds of positional minimization and
model building were carried out, in which all four subunits in the asym-
metric unit were refined with ncs restraints imposed. These restraints
were relaxed for residues involved in crystal contacts for which elec-
tron-density maps revealed evidence of different conformations in the
different subunits. Five additional zinc ions were included in the model,
of which four were on contacts between non-crystallographically
related subunits (coordinated by His229 and Asp387 of neighbouring
subunits, and two water molecules) and one between crystallographi-
cally related subunits (coordinated by Glu71 and Asp256 of crystallo-
graphically related subunits, and two water molecules). Attempts to
release the ncs restraints resulted in an increase in Rfree and a model
with worse geometry. The last round of refinement was carried out
including the 4% of data previously omitted.
The refined model
The refined model contains 389 residues out of 393, and includes 96
water molecules per subunit. The omitted residues are at the N and
C termini. Inspection of the (Fobs–Fcalc) electron-density map suggests
that residues Tyr159 and Tyr218 have two conformations, however,
given the limited resolution of the map, no attempt was made to model
this disorder. The crystallographic free R factor is 22.4% using a
random sample of 2536 reflections with no s cutoff between 20 and
2.5 Å resolution. The conventional R factor from the final round of
refinement is 19.6% using all data between 20 and 2.5 Å resolution.
The rms deviation from ideality is 0.007 Å in bond lengths and 1.34° in
bond angles. The mainchain dihedral angles for the majority of the
residues in the refined model (91.7%) lie in the most favoured regions,
and none of the non-glycine residues have mainchain dihedral angles
that lie in disallowed regions of the Ramachandran plot [56,57]. The
average temperature factor for all protein atoms is 37.5 Å2. The average
rms separation, for all subunits, of equivalent a carbon atoms in the
crystallographically independent monomers following superposition, is
0.19 Å. This separation only exceeds 1.0 Å for two residues at the
N terminus.
Accession numbers
The coordinates have been deposited in the Protein Data Bank with the
accession code 1CG2.
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